Progress on Bruton's Tyrosine Kinase Targeted Drugs

Bruton's tyrosine kinase(BTK) is a key kinase in the B cell antigen receptor signaling pathway, involved in B cell proliferation, differentiation and apoptosis, also associated with multiple signaling pathways and the occurrence and development of inflammation and tumors, has become an important target for the treatment of hematological malignancies and autoimmune diseases. The currently marketed BTK targeting drugs Ibrutinib, Acalabrutinib and Zanubrutinib have shown satisfactory clinical efficacy for B-cell malignancies. In addition, a number of drugs have entered clinical research and performed well. The proteolysis-targeting chimeras targeting BTK is a promising strategy to solve the resistance of Ibrutinib and promoting the development of BTK targeted drugs. This paper reviews the progress of BTK targeted drugs, and provides inspiration for further research of BTK targeted drugs.